Background: To prevent or delay the onset of psychotic disorders or ameliorate their course, prodromal research has strived to identify and treat individuals at risk of developing psychosis. While this approach is laudable, it is, however, not entirely unproblematic from clinical and conceptual perspectives. For example, it remains unclear how we are to understand the development from a nonpsychotic, distressing condition such as schizotypal disorder to a psychotic disorder such as schizophrenia? The current terminology on the subject implies either a nonlinear jump (“conversion”) or a more linear progression (“transition”) from one disorder to another. To enrich our understanding of such diagnostic shifts, we examined the psychopathological pictures of patients who “transitioned” from schizotypal disorder to schizophrenia. Methods: From a larger study on psychopathology, we examined 40 patients who were diagnosed with schizotypal disorder at baseline. At 5-year follow-up, 30 patients maintained the diagnosis of schizotypal disorder, while 10 were re-diagnosed with schizophrenia. We examined detailed descriptions of the 10 patients who progressed to schizophrenia, comparing psychopathology and level of functioning. Results: The level of functioning decreased slightly from baseline to follow-up in 9 out of 10 patients. Eight patients had previously had micro-psychotic or psychotic experiences. All patients had self-disorders at baseline, and several patients had perceptual disorders. Nine patients had formal thought disorders at baseline. The progression is illustrated by 2 cases. Conclusion: In this small study, we did not find any striking changes in any of the patients, neither in terms of psychopathological manifestations nor in terms of their level of functioning. Thus, rather than witnessing a genuine “conversion” or “transition” from schizotypal disorder to schizophrenia, we observed dimensional fluctuations within the same condition.

1.
Raballo
A
,
Larøi
F
.
Clinical staging: a new scenario for the treatment of psychosis
.
Lancet
.
2009 Aug 1
;
374
(
9687
):
365
7
. .
2.
Yung
AR
,
Yuen
HP
,
McGorry
PD
,
Phillips
LJ
,
Kelly
D
,
Dell’Olio
M
,
Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states
.
Aust N Z J Psychiatry
.
2005 NovDec
;
39
(
11–12
):
964
71
. .
3.
Miller
TJ
,
McGlashan
TH
,
Woods
SW
,
Stein
K
,
Driesen
N
,
Corcoran
CM
,
Symptom assessment in schizophrenic prodromal states
.
Psychiatr Q
.
1999 Winter
;
70
(
4
):
273
87
. .
4.
Yung
AR
,
Phillips
LJ
,
Yuen
HP
,
McGorry
PD
.
Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features
.
Schizophr Res
.
2004 Apr 1
;
67
(
2–3
):
131
42
. .
5.
Nelson
B
,
Yuen
HP
,
Wood
SJ
,
Lin
A
,
Spiliotacopoulos
D
,
Bruxner
A
,
Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: the PACE 400 study
.
JAMA Psychiatry
.
2013 Aug
;
70
(
8
):
793
802
. .
6.
Fusar-Poli
P
,
Borgwardt
S
,
Bechdolf
A
,
Addington
J
,
Riecher-Rössler
A
,
Schultze-Lutter
F
,
The psychosis high-risk state: a comprehensive state-of-the-art review
.
JAMA Psychiatry
.
2013 Jan
;
70
(
1
):
107
20
. .
7.
Yung
AR
,
Yuen
HP
,
Berger
G
,
Francey
S
,
Hung
TC
,
Nelson
B
,
Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk?
Schizophr Bull
.
2007 May
;
33
(
3
):
673
81
. .
8.
Raballo
A
,
Poletti
M
.
Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
Psychol Med
.
2019 Nov
;
29
:
1
4
. .
9.
Parnas
J
,
Nordgaard
J
,
Varga
S
.
The concept of psychosis: a clinical and theoretical analysis
.
Clin Neuropsychiatry
.
2010
;
7
(
2
):
32
7
.
10.
World Health Organization
.
Tenth revision of the international classification of diseases and related health problems (ICD-10)
.
Geneva
:
WHO Press
;
1992
.
11.
American Psychiatric Association
.
Diagnostic and statistical manual of mental disorders
. 5th ed.
Arlington
:
APA
;
2013
.
12.
Handest
P
,
Parnas
J
.
Clinical characteristics of first-admitted patients with ICD-10 schizotypal disorder
.
Br J Psychiatry Suppl
.
2005 Aug
;
48
:
s49
54
. .
13.
Yung
AR
,
Phillips
LJ
,
Yuen
HP
,
Francey
SM
,
McFarlane
CA
,
Hallgren
M
,
Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group
.
Schizophr Res
.
2003 Mar 1
;
60
(
1
):
21
32
. .
14.
Parnas
J
,
Raballo
A
,
Handest
P
,
Jansson
L
,
Vollmer-Larsen
A
,
Saebye
D
.
Self-experience in the early phases of schizophrenia: 5-year follow-up of the Copenhagen Prodromal Study
.
World Psychiatry
.
2011 Oct
;
10
(
3
):
200
4
. .
15.
McGuffin
P
,
Farmer
A
,
Harvey
I
.
A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system
.
Arch Gen Psychiatry
.
1991 Aug
;
48
(
8
):
764
70
. .
16.
Kay
SR
,
Fiszbein
A
,
Opler
LA
.
The positive and negative syndrome scale (PANSS) for schizophrenia
.
Schizophr Bull
.
1987
;
13
(
2
):
261
76
. .
17.
Gross
G
,
Huber
G
,
Klosterkötter
J
,
Linz
M
.
Bonner Skala Für die Beurteilung von Basissymptomen
.
Berlin: Springer
;
1987
.
18.
Nordgaard
J
,
Handest
P
,
Vollmer-Larsen
A
,
Saebye
D
,
Pedersen
JT
,
Parnas
J
.
Temporal persistence of anomalous self-experience: a 5-years follow-up
.
Schizophr Res
.
2017 Jan
;
179
:
36
40
.
19.
Parnas
J
,
Møller
P
,
Kircher
T
,
Thalbitzer
J
,
Jansson
L
,
Handest
P
,
EASE: examination of anomalous self-experience
.
Psychopathology
.
2005 Sep-Oct
;
38
(
5
):
236
58
. .
20.
Nordgaard
J
,
Revsbech
R
,
Sæbye
D
,
Parnas
J
.
Assessing the diagnostic validity of a structured psychiatric interview in a first-admission hospital sample
.
World Psychiatry
.
2012 Oct
;
11
(
3
):
181
5
. .
21.
Nordgaard
J
,
Sass
LA
,
Parnas
J
.
The psychiatric interview: validity, structure, and subjectivity
.
Eur Arch Psychiatry Clin Neurosci
.
2013 Jun
;
263
(
4
):
353
64
. .
22.
Jansson
L
,
Nordgaard
J
.
The psychiatric interview for differential diagnosis
.
Cham
:
Springer
;
2016
.
23.
Bleuler
E
.
Dementia praecox or the group of schizophrenias
.
New York
:
International Universities Press
;
1950
.
24.
Henriksen
MG
,
Parnas
J
.
Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance
.
Schizophr Bull
.
2014 May
;
40
(
3
):
542
7
. .
25.
Feyaerts
J
,
Henriksen
MG
,
Vanheule
S
,
Myin-Germeys
I
,
Sass
LA
.
Delusions beyond beliefs: a critical overview of diagnostic, aetiological, and therapeutic schizophrenia research from a clinical-phenomenological perspective
.
Lancet Psychiatry
.
2021 Mar
;
8
(
3
):
237
49
. .
26.
Arendt
M
,
Rosenberg
R
,
Foldager
L
,
Perto
G
,
Munk-Jørgensen
P
.
Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases
.
Br J Psychiatry
.
2005 Dec
;
187
:
510
5
. .
27.
Penn
DL
,
Guynan
K
,
Daily
T
,
Spaulding
WD
,
Garbin
CP
,
Sullivan
M
.
Dispelling the stigma of schizophrenia: what sort of information is best?
Schizophr Bull
.
1994
;
20
(
3
):
567
78
. .
28.
Peris
TS
,
Teachman
BA
,
Nosek
BA
.
Implicit and explicit stigma of mental illness: links to clinical care
.
J Nerv Ment Dis
.
2008 Oct
;
196
(
10
):
752
60
. .
29.
Tranulis
C
,
Park
L
,
Delano
L
,
Good
B
.
Early intervention in psychosis: a case study on normal and pathological
.
Cult Med Psychiatry
.
2009 Dec
;
33
(
4
):
608
22
. .
30.
Jansson
L
,
Handest
P
,
Nielsen
J
,
Sæbye
D
,
Parnas
J
.
Exploring boundaries of schizophrenia: a comparison of ICD-10 with other diagnostic systems in first-admitted patients
.
World Psychiatry
.
2002 Jun
;
1
(
2
):
109
14
.
31.
Morgan
VA
,
Castle
DJ
,
Jablensky
AV
.
Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian National Study of Low Prevalence (Psychotic) disorders
.
Aust N Z J Psychiatry
.
2008 Jan
;
42
(
1
):
74
82
. .
32.
Nawka
A
,
Kalisova
L
,
Raboch
J
,
Giacco
D
,
Cihal
L
,
Onchev
G
,
Gender differences in coerced patients with schizophrenia
.
BMC Psychiatry
.
2013 Oct 11
;
13
:
257
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.